• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    I-Mab Receives Nasdaq Notice on Minimum Bid Price Requirement

    GLOBENEWSWIRE

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    PR NEWSWIRE

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    PR NEWSWIRE

    I-Mab Ragistomig Phase 1: Encouraging Pd-L1X4-1Bb At Asco 2024

    GLOBENEWSWIRE

    I-MAB Filed 2023 Annual Report on Form 20-F

    PR NEWSWIRE

    I-Mab CEO details considerations behind China split, hints in-licensing

    ENDPTS

    I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

    PR NEWSWIRE

    Three more I-Mab execs exit after US/China operations split

    ENDPTS

    I-Mab Reports Full Year 2023 Financial Results and Business Update

    PR NEWSWIRE

    AbbVie terminates deal with I-Mab to develop cancer drug

    REUTERS

    I-Mab to Report Mid-Year 2023 Financial Results

    PR NEWSWIRE

    I-Mab Announces the Appointment of Raj Kannan as CEO

    PR NEWSWIRE

    I-Mab Announces Outcome in Arbitration Relating to Agreements with Tracon

    PR NEWSWIRE

    I-Mab Announces Two Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

    PRNEWSWIRE

    I-Mab to Present CD47 Antibody Lemzoparlimab & CD73 Antibody Uliledlimab

    PRNEWSWIRE

    I-Mab Announces Approval to Initiate PIII Study of Lemzoparlimab & Azacitidine

    PRNEWSWIRE

    I-Mab Announces Positive Phase 2 Data of Lemzoparlimab with Azacitidine

    PRNEWSWIRE

    I-Mab to Present PII Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

    PRNEWSWIRE

    I-Mab Reports Financial Results for the Six Months Ended June 30, 2022

    PRNEWSWIRE

    China and US consider possible solution for US-listed companies

    ENDPTS

    I-Mab Announces Share Purchase Plans by the Company and the Senior Management

    PRESS RELEASE

    I-Mab to Report Financial Results for the Six Months

    PRNEWSWIRE

    AbbVie calls off PI trial for I-Mab’s CD47 after Zai Lab shelves program

    ENDPTS

    I-Mab Begins Dosing in PI Trial of Claudin 18.2 and 4-1BB Bispecific Ab TJ-CD4B

    PRNEWSWIRE

    BMS vets tie up another all-stock deal

    ENDPTS

    AbbVie terminates early-stage study of I-Mab`s antibody

    ENDPTS

    I-Mab to Present PII Data of CD47 Ab Lemzoparlimab at ESMO 2022

    PRESS RELEASE

    I-Mab to Host 2022 R&D Day

    PRNEWSWIRE

    I-Mab Receives Top Rankings in Five Categories by Institutional Investor

    PRNEWSWIRE

    I-Mab Partner MorphoSys Announces License Agreements for Felzartamab and TJ210

    PRNEWSWIRE

    Genexine Completes Enrollment in PIII Trial with GX-H9/TJ101

    BIOSPACE

    I-Mab concludes subject enrolment in Phase III PGHD treatment trial

    CLINICALTRIALSARENA

    I-Mab Completes Patient Enrollment in PIII Trial of Eftansomatropin alfa

    PRNEWSWIRE

    I-Mab, Junshi`s cancer combo worked best as first-line treatment

    FIERCEBIOTECH

    I-Mab Reports Latest PII Data of its Differentiated CD73 Antibody Uliledlimab

    ASIAONE

    I-Mab to Hold Investor Call to Report Latest PII Data of Uliledlimab

    PRNEWSWIRE

    I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

    PRNEWSWIRE

    Chinese biotech I-Mab spikes on report of buyout interest (updated)

    SEEKING ALPHA

    I-Mab Appoints Richard Yeh as COO and John Hayslip as CMO

    PRNEWSWIRE

    I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management

    PRNEWSWIRE

    I-Mab Reports Financial Results for the Year Ended December 31, 2021

    PRNEWSWIRE

    NRx Pharma Appoints Ira Strassberg as Chief Financial Officer and Treasurer

    PRNEWSWIRE

    I-Mab to Report FY 2021 Financial Results on March 29

    PRNEWSWIRE

    Psycheceutical says Agreement with Vici Health Sciences

    PRNEWSWIRE

    I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act

    PRNEWSWIRE

    Another strike for biotech: China

    EVALUATE

    I-Mab Announces Multiple Presentations at the 2022 AACR

    PRNEWSWIRE

    I-Mab Receives FDA ODD for Novel Claudin 18.2 x 4-1BB Bispecific Ab TJ-CD4B

    PRNEWSWIRE

    I-Mab Partners to Localize Manufacturing & Accelerate Commercialization

    PRNEWSWIRE

    I-Mab Begins Dosing in Phase 2 Comb. Trial of Lemzoparlimab with Toripalimab

    PRNEWSWIRE

    I-Mab Begins Dosing in Phase 2 Trial of Efineptakin Alfa+Pembrolizumab

    PRNEWSWIRE

    NMPA Approves I-Mab`s Phase 2 Trial of Enoblituzumab + Pembrolizumab

    PRNEWSWIRE

    I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Devp

    PRNEWSWIRE

    I-Mab Receives IND Approval for Phase 1 Trial of TJ-CD4B in Solid Tumors

    PRNEWSWIRE

    I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project

    ASIAONE

    I-Mab to Hold Investor Call for Clinical Data of Lemzoparlimab + Rituximab

    PRNEWSWIRE

    I-Mab doses first two subjects in solid tumour treatment trial in US

    CLINICALTRIALSARENA

    Nasal Vaccine Starts Trial to Protect Against Alzheimer`s

    BIOSPACE

    I-Mab and Jumpcan Announce Strategic Partnership on Eftansomatropin Alfa

    PRNEWSWIRE

    I-Mab & ABL Bio Report Preclinical Data 4-1BB-targeting Bispecific Antibodies

    PRNEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.